Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

NCT00320801 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

188

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated early due to administrative reasons.

Conditions

Osteoarthritis

Interventions

DRUG: Buprenorphine transdermal patch
DRUG: Buprenorphine transdermal patch

Sponsor

Purdue Pharma LP